Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
Want to see GPCR full AI Analyst Report?
GPCR Stock Chart & Stats
$50.75
-$0.32(-1.18%)
At close: 4:00 PM EST
$50.75
-$0.32(-1.18%)
Day’s Range― - ―
52-Week Range$15.80 - $94.90
Previous CloseN/A
Volume219.80K
Average Volume (3M)784.75K
Market Cap
$2.80B
Enterprise Value$1.95B
Total Cash (Recent Filing)$1.46B
Total Debt (Recent Filing)$5.79M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Aug 06, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.64
Shares Outstanding71,074,520
10 Day Avg. Volume615,912
30 Day Avg. Volume784,753
Financial Highlights & Ratios
PEG Ratio-11.37
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-18.23
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.60K
Enterprise Value/Ebitda-10.27
Forecast
1Y Price Target
$111.50Price Target Upside119.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.38
Revenue Forecast (FY)$37.50M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And LiquidityA large equity base and negligible leverage give Structure Therapeutics multi-year funding flexibility to support late-stage programs without immediate solvency pressure. This durable financial cushion allows continued R&D investment and reduces the likelihood of forced distressed financings while trials progress.
De-risked Lead Obesity Program With Regulatory ProgressRobust Phase 2 efficacy (≈16% weight loss, durable to extended follow-up) combined with constructive FDA end-of-Phase-2 feedback materially improves the probability of a disciplined Phase 3 path. This structural progress raises the program's commercial and regulatory credibility over the medium term.
Experienced Commercial And Legal Leadership AddedBringing in a senior executive with late-stage development, commercialization and M&A track record strengthens operational execution as the company transitions to Phase 3 and eventual launch planning. Improved governance and commercial expertise are durable positives for program execution.
Bears Say
Pre-revenue With Widening Operating LossesAs a pre-revenue biotech with expanding operating losses, the company remains dependent on successful clinical outcomes to generate future revenue. Persistent negative earnings elevate execution risk and mean long-term investor returns hinge heavily on trial success and commercialization timing.
High And Accelerating Cash BurnSustained negative operating and free cash flow highlight heavy funding needs to advance multiple clinical programs. Accelerating FCF deterioration increases reliance on capital markets or equity raises, raising the probability of dilution and constraining optionality if trial timelines extend.
Expanded ATM Raises Dilution RiskWhile an uncapped $400M ATM boosts financing flexibility, it also creates a durable pathway for meaningful future equity issuance. Reliance on sizable share raises can dilute existing holders and compress per-share economics unless clinical and commercial milestones consistently justify new capital.
Structure Therapeutics, Inc. Sponsored ADR News
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $15.80 and its highest was $94.90 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $2.80B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Aug 06, 2026 which is in 64 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on May 07, 2026. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.351 by $0.001.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.37.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 71,074,520 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.351. Following the earnings report the stock price went down -0.128%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$111.50 (119.70% Upside)
$111.50 (119.70% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 475.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
77.15%
12-Months-Change
Fundamentals
Return on Equity
-15.14%
Trailing 12-Months
Asset Growth
74.04%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
GPCR Stock 12 Month Forecast
Average Price Target
$111.50
▲(119.70% Upside)
Technical Analysis
Ownership Overview
10.08% Insiders
25.03% Mutual Funds
44.57% Other Institutional Investors
18.22% Public Companies and Individual Investors